Cosmetic laser iridoplasty assessed by Catalan AQuAS

04

Nov 2019

In early October 2019, the Health Evaluation and Quality Agency of Catalonia (AQuAS) published the assessment of cosmetic laser iridoplasty. This technique reduces the density of the brown pigment in the iris, to obtain a green or blue color permanently, unlike the opaque colored contact lenses. The procedure is used either for patient’s own wish (no physical condition), or to treat heterochromia.

AQuAS was given the task from the Catalan healthcare authorities to assess this procedure, more specifically, to assess its safety, efficacy, cost and ethical impact.

Five (5) studies have been included for this report: a single cohort study with 90 cases (180 eyes), one (1) series of seven cases (eight eyes), one (1) case study, one (1) study of 12 cases in rabbits and one (1) study in cadavers. None of these studies had follow-up time greater than two years. There is no evidence comparing iridoplasty and opaque contact lenses in clinical trials.

Conclusions:

  • Regarding effectiveness, the change of the color of the iris is visible after 1-3 sessions. At least 1-2 more sessions are required to remove additional residual or new pigment
  • The patient can choose the exact color they want, but the outcome cannot be guaranteed
  • The most common adverse event is increased intraocular pressure, which is treated pharmacologically. Sensitivity to light and other minor complications occur in 2% of the cases
  • The total cost of this technique is €2500-€4500, depending on the basic color of the iris
  • Every second person who undergoes this procedure is not fully satisfied
  • The risk-benefit ratio is still not well defined, because the outcomes are uncertain and potentially irreversible
  • It is recommended to undergo this intervention exclusively within clinical investigation settings and after getting approval by the ethics committee

See the complete report in Catalan here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more